Enzymatica AB (FRA:EN9) Moat Score: 0/10 (As of Jul. 07, 2026)


FRA:EN9 Enzymatica AB FRA:EN9
36 GF Score
Price €0.18
GF Value €0.16
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB Moat Score?

Enzymatica AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Enzymatica AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Enzymatica AB might have No Moat - No discernible moat.

Enzymatica AB  (FRA:EN9) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Enzymatica AB Moat Score Related Terms

FRA:EN9
36GF Score
Enzymatica AB FRA:EN9
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.18 is trading 13.8% above its estimated GF Value™ of €0.16. GuruFocus considers Enzymatica AB to be Modestly Overvalued.

Key valuation signals for FRA:EN9:

  • Moat Score: 0
  • GF Value™: €0.16 vs. price of €0.18 (13.8% above fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
36GF Score

Get the complete analysis for FRA:EN9

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€0.16
GF Value